Brown S J, Slizofski W J, Dadparvar S
Department of Radiation Oncology and Nuclear Medicine, Hahnemann University Hospital, Philadelphia, Pennsylvania 19102.
J Nucl Med. 1990 Jan;31(1):115-7.
Markedly altered biodistribution of [67Ga]citrate was observed in a 66-yr-old hemodialysis patient imaged at 48 hr postinjection. A review of the patient's hospital records revealed toxic serum levels of aluminum, treated with the chelating agent desferoxamine. Based on what is known about the biologic interactions between gallium, aluminum, transferrin, and desferoxamine, we believe that both toxic serum aluminum levels and desferoxamine therapy may cause altered biodistribution on [67Ga]citrate scintigraphy.
在一名66岁的血液透析患者注射后48小时进行成像时，观察到[67Ga]柠檬酸盐的生物分布发生了显著改变。查阅该患者的医院记录发现其血清铝水平有毒，曾用螯合剂去铁胺进行治疗。基于已知的镓、铝、转铁蛋白和去铁胺之间的生物学相互作用，我们认为血清铝水平有毒和去铁胺治疗都可能导致[67Ga]柠檬酸盐闪烁扫描的生物分布改变。
